Tissue Kallikrein Preventing the Restenosis after Stenting of Symptomatic MCA Atherosclerotic Stenosis (KPRASS)

Abstract

Rationale

Many recent studies suggest that the kallikrein-kinin system play a protective role in the impairment of vascular smooth muscle cells and vascular endothelial cell.

Aims

The study aims to determine whether tissue kallikrein is efficacy for preventing the long-term in-stent restenosis after stenting of symptomatic atherosclerotic stenosis of the middle cerebral artery M1 segment.

Design

This is a Phase II, randomized, single-blinded, controlled trial. In line with SAMMPRIS stenting indications, patients (n = 90) with the symptomatic the middle cerebral artery M1 segment stenosis ⩾70% and successfully treated with stent will be enrolled. Eligible patients will be randomized using computer generated numbers, and allocated to receive tissue kallikrein treatment or not. Patients in tissue kallikrein treatment group will be prescribed with intravenous infusion of tissue kallikrein (0·15 PNAU/d, dissolved in 100 ml saline) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet (240 U, 3/d) to the end of study. As the foundation treatment, all the enrolled patients will receive aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.

Study outcomes

Patients will be evaluated at 1, 6 and 12 months after stenting. The primary outcomes are the in-stent restenosis rate, new stroke or aggravation of the previous ischemic stroke ipsilateral to the severe stenotic artery. Secondary outcomes include stroke of other artery territories, myocardial infarction and vascular death. Modification of stroke knowledge, exercise and diet habit, smoking cessation and available laboratory data will also be recorded.

Conclusion

As our pilot study, tissue kallikrein would be expected to prevent the long-term in-stent restenosis after stenting of the symptomatic middle cerebral artery dramatically.

Keywords

atherosclerotic stenosis in-stent restenosis ischemic stroke the middle cerebral artery tissue kallikrein

Get full access to this article

View all access options for this article.

References

Sacco

Kargman

. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995; 26: 14–20.

Wong

. Global burden of intracranial atherosclerosis. Int J Stroke 2006; 1: 158–9.

Chimowitz

Lynn

Howlett-Smith

. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–16.

Kasner

Chimowitz

Lynn

. Predictors of ischaemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113: 555–63.

Famakin

Chimowitz

Lynn

. Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis. Stroke 2009; 40: 1999–2003.

Lutsep

. Symptomatic intracranial stenosis: Best medical treatment vs. intracranial stenting. Curr Opin Neurol 2009; 22: 69–74.

Chimowitz

Lynn

Derdeyn

. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993–1003.

Hussain

Fraser

Abruzzo

. Standard of practice: Endovascular treatment of intracranial atherosclerosis. J Neurointerv Surg 2012; 4: 397–406.

Liu

. Beyond the time window of intravenous thrombolysis: Standing by or by stenting? Intervent Neurol 2012; 1: 3–15.

10.

Groschel

Schnaudigel

Pilgram

Wasser

Kastrup

. A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke 2009; 40: e340–7.

11.

Zhu

Zhang

Liu

. Predictive factors for in-stent restenosis after balloon-mounted stent placement for symptomatic intracranial atherosclerosis. Eur J Vasc Endovasc Surg 2010; 40: 499–506.

12.

Yue

Yin

. Comparison of BMSs with SES for Symptomatic Intracranial Disease of the Middle Cerebral Artery Stenosis. Cardiovasc Intervent Radiol 2011; 34: 54–60.

13.

Klein

Rosenblum

. Restenosis after successful percutaneous transluminal coronary angioplasty. Prog Cardiovasc Dis 1990; 32: 365–82.

14.

Anstin

Ratliff

Hollman

Tabei

Phillips

. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369–75.

15.

Xia

Yin

Borlongan

. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 2004; 43: 452–9.

16.

Tang

Shao

. The Protein Therapy of Kallikrein in Cerebral Ischemic Reperfusion Injury. Curr Med Chem 2009; 16: 4502–10.

17.

Liu

Zhang

Liu

. Tissue kallikrein protects cortical neurons against in vitro ischemia-acidosis/reperfusion-induced injury through the ERK1/2 pathway. Exp Neurol 2009; 219: 453–65.

18.

Emanueli

Salis

Chao

. Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice. Arterioscler Thromb Vasc Biol 2000; 20: 1459–66.

19.

Murakami

Yayama

Miao

Wang

Chao

. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 1999; 34: 164–70.

20.

Porcu

Emanueli

Desortes

. Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 1104–10.

21.

Samuels

Joseph

Lynn

. Standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000; 21: 643–6.